Ghia
‘There was a buy bit operating all last week so rest assured someone is buying at this price on the sly.’
You must be watching another game to me as buying frequency and volume was extremely poor last week/this week.
Have you got access to L2 trading?
We are at an all time low in terms of volume/interest.
I’m sure the BOd are busy working hard, mind.
Dunk
Tbf Ghia has always been a very reliable and well researched poster and it’s good to have him back.
Unfortunately, this has all descended into oneupmanship as a result of their being no real updates from the company and the lengthy timelines expected.
Active results are interesting for me.
There must be a reason for the extended delay? I’m thinking a little like they are either keeping all the aces up their sleeve until they find out how to best to use the data or maybe the data wasn’t that good so what’s the rush, which would be slightly confusing given that we progressed to P3.
Did RM and SSH say many times ‘we know it works?’
Were we on a trial just a while ago?
Did we fail to meet the endpoints?
Stop ramping this share up to ridiculous heights.
We are 27p with very few trades, for a reason.
I’m stuck here for the foreseeable future but people need to beware.
Activ news has been incoming since last October.
No LC data, yet.
Promises of being on a new trial, all ifs and buts and when this happens only time will tell as the company is very poor at keeping investors in the loop.
Interferon use has been touted about forever on this board, but so far we don’t have a drug on the market.
These are the facts.
Of course, I would like the price to go up considerably and I’ll be out but I can’t see it for a long time, if at all.
Keep smiling.
Ghia was a very informative contributor back in the day as far as I’m concerned.
Tommy has done some incredible research, also.
Docneeda deserves the same accolade.
Manifesto has contributed lots of information for the board.
All these snippets of supporting evidence from these contributors, along with many others encouraged me to read lots of the overwhelming evidence available on SNG and then my hard earned cash followed.
If I could sell my shares for a reasonable return, I would.
The reality is that the company are very slow to act, although I also realise that the pharmaceutical industry is like this as the drugs normally take many years to come to fruition.
They are also very poor communicators, which is my main frustration with them.
I see them solely as a research company at this present time and I don’t think they have the credentials or the know how to bring a drug to market.
Well done to the aforementioned posters. Don’t get involved in the petty squabbles as you are all more intelligent than that.
Let’s hope all of the information you provide comes good for our Company and drug.
Sharedealer
You are a nasty piece of work and very immature.
Grow up!
Filtered.
Keyboard warriors.
The SP is still 28-30 pence.
Just saying.
No news is good news.
What a ridiculous comment.
Agreed MrC.
I too am heavily invested on a large paper loss.
I don’t see many positives here, currently.
I try to look at the facts, not ‘ifs’ and ‘maybes’ or ‘possibly’.
To many rampers on here that can’t accept that the trial failed and we are currently not on any trial.
We have been waiting for A2 feedback since Oct 2021.
I normally say good luck; we certainly need it.
SD
Nope
Before this is at the 22p level that we got on that terrible data release day.
Don’t want to be out of tangos over the weekend….
Not sure if you’re aware, but the SP is 28p.
Ramp or deramp all you want.
Disastrous - FACT!
At these prices.
GLA
Wigster/doc
Many thanks for your excellent posting; it is much appreciated.
First class!
Lots of NOs from the Bod in the discussion, which is unsurprising.
‘the main point was that to attract/retain the calibre of people that Synairgen need to push forward and commercialise SNG001, they need salaries to be commensurate with industry standards/levels.’
Interesting and out of touch!
Many thanks, again.
My strategy is the same as Ghias.
Return at monthly/quarterly intervals to see what/if any progress has been made in this long journey.
ATB
Tommy
Of course it would be cheap to save a life, as I too stated.
Current SOC has been proven to save lives for a lot less than our drug costs.
Of course I hope I am very wrong and we suddenly get included on a platform trial, preferably in the US and that A2 data arrives and is excellent.
I’m just looking at the facts thus far, not hearsay or speculation.
Yes, I will be watching for the synopsis from Doc and wigster, etc.
ATB
Let’s face facts.
Who is going to use our product at £2k cost, unless it will save a life?
Any takers; I doubt it.
It is not cost friendly to treat flu or the common cold.
Usual response: we are having loads of discussion with potential ventures/trials.
What else can the BOD say?
We may find a market eventually for a certain sub group, but it’s way off at the moment.
No A2 data which I’m pretty sure is average, otherwise it would already be being investigated to prepare for the next variants or pandemic.
Let’s wait for another trial and then see what’s what.
GLA
Thanks doc for the brief feedback.
No need to know what’s happening on the Reddit board; apparently, in the place where the sun shines they already have the A2 data as they received it before the company did
The SP is just above where it was in Feb. Whatever rubbish is spouted or positivity shared the SP remains stagnant.
SP going nowhere until a TO happens.
University spin off that will not bring the drug to market, as they don’t have the capabilities to do so, imo.
Before you say it, yes I’m still invested for the long term but I certainly haven’t got my head in the sand like many on here, simply believing it will still happen.
Two very positive RNS’s and still the price stays the same.
Mmmm.
Whatever responses are given in the AGM, the SP on the day will no doubt plummet.
This is due to the lengthy timelines and investor patience that is required for the new trials to commence.
Unless, of course, there is a data driven RNS prior to the day or one which identifies acceptance onto a new trial.
ATB
Polar left a while ago, well documented.